Abstract:Background: Cardiovascular toxicity represents a significant adverse consequence of cancer therapies, yet there remains a paucity of effective biomarkers for its timely monitoring and diagnosis. To give a first evidence able to elucidate the role of Growth Differentiation Factor 15 (GDF15) in the context of cancer diagnosis and its specific association with cardiac indicators in cancer patients, thereby testing its potential in predicting the risk of CTRCD (cancer therapy related cardiac dysfunction). Methods: Analysis of differentially expressed genes (DEGs), including GDF15, was performed by utilizing data from the public repositories of the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Cardiomyopathy is the most common heart disease and its main clinical manifestations, such as heart failure and arrhythmia, are similar to those of CTRCD. Examination of GDF15 expression was conducted in various normal and cancerous tissues or sera, using available database and serum samples. The study further explored the correlation between GDF15 expression and the combined detection of cardiac troponin-T (c-TnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), assessing the combined diagnostic utility of these markers in predicting risk of CTRCD through longitudinal electrocardiograms (ECG). Results: GDF15 emerged as a significant DEG in both cancer and cardiomyopathy disease models, demonstrating good diagnostic efficacy across multiple cancer types compared to healthy controls. GDF15 levels in cancer patients correlated with the established cardiac biomarkers c-TnT and NT-proBNP. Moreover, higher GDF15 levels correlated with an increased risk of ECG changes in the cancer cohort. Conclusion: GDF15 demonstrated promising diagnostic potential in cancer identification; higher GDF15, combined with elevated cardiac markers, may play a role in the monitoring and prediction of CTRCD risk.

HDGF: a Novel Jack-of-all-trades in Cancer.

Prognostic role of hepatoma-derived growth factor in solid tumors of Eastern Asia: a systematic review and meta- analysis.

Relationship of HDGF or VEGF expression with hepatocellular carcinoma angiogenesis:report of 108 cases

Interactome Study Suggests Multiple Cellular Functions of Hepatoma-Derived Growth Factor (HDGF)

Clinical and Biological Significance of Hepatoma-Derived Growth Factor in Ewing's Sarcoma.

Downregulated Expression of Hepatoma-Derived Growth Factor (HDGF) Reduces Gallbladder Cancer Cell Proliferation and Invasion

Hypothesis paper: GDF15 demonstrated promising potential in Cancer diagnosis and correlated with cardiac biomarkers

Hepatoma‐derived Growth Factor Involved in the Carcinogenesis of Gastric Epithelial Cells Through Promotion of Cell Proliferation by Erk1/2 Activation

A Novel HDGF-ALCAM Axis Promotes the Metastasis of Ewing Sarcoma Via Regulating the GTPases Signaling Pathway

Role of Hepatoma‐derived Growth Factor in Promoting De Novo Lipogenesis and Tumorigenesis in Hepatocellular Carcinoma

The Dual Role and Therapeutic Potential of High-Mobility Group Box 1 in Cancer

Multiple functions of HMGB1 in cancer

Advancements in the Research of GEF-H1: Biological Functions and Tumor Associations

Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers

The function and clinical implication of YTHDF1 in the human system development and cancer

Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity

Downregulated Expression Of Hepatomaderived Growth Factor Inhibits Migration And Invasion Of Prostate Cancer Cells By Suppressing Epithelial- Mesenchymal Transition And Mmp2, Mmp9

HDGF Promotes Gefitinib Resistance by Activating the PI3K/AKT and MEK/ERK Signaling Pathways in Non-Small Cell Lung Cancer

Comprehensive pan‐cancer analysis of MTDH for human tumor prognosis and as an immunological biomarker including breast and kidney cancer

HMGB1 in Cancer: Good, Bad, or Both?

Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis